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ABSTRACT 
 
The worldwide prevalence of type 2 diabetes mellitus (T2DM) has surpassed more than 380 million people in 
2014 and the projections of new T2DM cases for the next years are not encouraging. At present, combination 
of diet and exercise do not guarantee an adequate control of glucose homeostasis in T2DM patients. Thus, 
oral agents that act improving peripheral insulin sensitivity and/or pancreatic beta-cell function are additionally 
used as monotherapy or in combination. However, many patients still experience inadequate control with the 
pharmacotherapy ‘weapons’ currently available. Canagliflozin is a novel selective inhibitor of sodium-glucose co-
transporter 2 (SGLT2) that lowers blood glucose concentration mainly by augmenting urinary glucose excretion. 
Besides  having an effective action in reducing HbA1c, canagliflozin treatment also may benefit those patients 
aiming to control body weight, blood pressure and hypoglycemia episodes since this drug positively impact on 
such parameters. Among the adverse effects, genital infections are the most frequent. Much caution is required 
for some groups of patients including those elderly and with chronic kidney disease since canagliflozin can 
worse their quality of life. Given its overall cardiometabolic improvements, canagliflozin seems to be an 
important ally to the treatment of a selective group of T2DM patients and its efficacy and safety must be kept 
under monitoring through long-term clinical trials as well as experimental studies to certify whether this class of 
drug comes to stay among T2DM therapy. 
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Introduction 
According to the sixth edition of Diabetes 
Atlas, released by the International Diabetes 
Federation, the prevalence of diabetes worldwide in 
2014 is around 8.3% of the total population, which 
consists of approximately 387 million people. The 
IDF Diabetes Atlas also reveals an estimated 
increment of 205 million new diabetes cases by 2035.1 
This scenery can become more worrying when 
considering that more than 470 million people will 
have prediabetes (intermediate hyperglycemia) by 
2030; a state of high-risk diabetes development.2 
Around 90-95% of people diagnosed with 
diabetes  belong to the  type 2 diabetes mellitus 
(T2DM) category, a chronic disease of multifactorial 
origin that includes genetic susceptibility, lifestyle 
(increased inactivity together with increased 
hypercaloric diet) and metabolic programming at 
prenatal and/or postnatal periods among other 
factors.3 In general, the altered glucose homeostasis in 
T2DM is initially managed with an oral agent, mostly 
metformin (biguanide class) treatment. However, due 
to T2DM progressive nature, monotherapy is normally 
associated with a high failure rate until the fifth year of 
treatment.4 Thus, association with a second therapy 
that includes agents with complementary action 
mechanisms (e.g., sulfonylureas, thiazolidinediones, 
incretin mimetic drugs) is required for adequate 
control of glucose homeostasis and to reduce adverse 
effects.5  
The main focus of therapeutic strategies that 
include the aforementioned drugs has been on agents 
that act by improving peripheral insulin sensitivity 
and/or beta-cell function (insulin secretion). However, 
at present, no monotherapy is efficient  to achieve 
acceptable, long-lasting glycemic control in the 
majority of patients, which has led to scientific efforts 
on developing novel drugs with improved efficacy and 
safety.6 
 
Canagliflozin - sodium-glucose co-transporter 
2 (SGLT2) inhibitor 
Canagliflozin, a novel selective inhibitor of 
sodium-glucose co-transporter 2 (SGLT2), appears as 
an important pharmacotherapy to handle the 
imbalanced glucose homeostasis in diabetes since it 
blocks the reabsorption of filtered glucose in the 
kidneys.7 As SGLT2 is found exclusively in the 
kidneys8, canagliflozin is not expected to impair 
intestinal glucose absorption since brush border of the 
small intestine express exclusively SGLT1.9 
Commercialization of canagliflozin, the first SGLT2 
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inhibitor drug, (commercially named INVOKANA®) 
was approved by the United States Food and Drug 
Administration (FDA) and by the European Medicines 
Agency (EMA) in 2013. Meta-analysis studies have 
demonstrated that canagliflozin promotes significant 
glycosuria favoring not only the improvement of 
glycemic control but also the weight loss as a result of 
caloric loss. Additionally, it improves the blood 
pressure (BP) parameters.10,11 
 
Canagliflozin – the evidence and perils   
In a phase I placebo-controlled study with 
healthy men receiving a single dose of canagliflozin 
(varying from 30 to 800 mg), it was demonstrated that 
canagliflozin decreased the calculated 24-h mean renal 
threshold for glucose (RTG), achieving a maximal 
reduction to approximately 60 mg/dL and augmented 
24-h mean urinary glucose excretion (UGE). 
Individuals subjected to canagliflozin treatment at 
doses over 200 mg before breakfast had attenuated 
plasma glucose and insulin increment during that 
meal.12 Transient postural dizziness and headache were 
the most frequent (8%) adverse effects.12 Phase Ib 
placebo-controlled study confirmed the canagliflozin 
potential to reduce RTG and to increase UGE after 28 
days of treatment in T2DM patients suboptimally 
controlled on insulin and receiving one oral 
antihyperglycemic agent.13 These patients also had 
reduced fasting plasma glucose (FPG) and HbA1c 
values, and presented body weight loss mainly at 300 
mg dosage regimen with similar adverse effects among 
groups. A dose-ranging, placebo-controlled, 
multicenter, 12-week study with T2DM patients 
inadequately controlled with metformin monotherapy 
demonstrated that canagliflozin added onto metformin 
significantly improved glycemic control compared to 
placebo and sitagliptin groups.14 This was paralleled 
with a significant weight loss and low incidence of 
hypoglycemia. The safety and tolerability of 
canagliflozin treatment in these patients were 
favorable except for increased frequency of genital 
infection in females.14 The weight loss caused by 
canagliflozin treatment were also investigated in a 
phase 2b, 12-wk study with overweight/obese patients 
without T2DM showing that canagliflozin 
administration resulted in reduction of body weight 
around 2.5% compared to 1.3% in placebo. This was 
also paralleled with increased urinary adverse effects in 
women.15 By these first clinical studies, it was 
reasonably acceptable that canagliflozin treatment 
could render significant improvements in the glycemic 
control that might be tested in more prolonged 
studies. 
The long-term safety and efficacy profile of 
canagliflozin treatment were investigated along phase 
III studies conducted from 26 to 52 weeks in T2DM 
patients as add-on therapy to diet and exercise16, 
metformin monotherapy17, metformin plus 
sulfonylurea18,19, metformin plus pioglitazone20, and to 
insulin-treated patients.21 In general, canagliflozin 
treatment at 100 and 300 mg produced significant 
improvement in glycemic control, although it was 
mostly accompanied by increased genital infections in 
females. Canagliflozin treatment at 100 and 300 mg 
improved glycemic parameters and reduced body 
weight after 26-week treatment in T2DM patients 
inadequately controlled with diet and exercise.16  In 
patients being treated with metformin plus 
sulfonylurea, canagliflozin treatment at doses of 100 
and 300 mg ameliorated the HbA1c and FPG after 52-
weeks of therapy compared to placebo- or sitagliptin-
treated patients.18,19 In another phase III study with 
T2DM patients managed with metformin plus 
pioglitazone, canagliflozin treatment at 100 and 300 
mg improved the glycemic and blood pressure (BP) 
parameters after a 52-week period.20 When added to 
insulinotherapy, canagliflozin treatment reduced 
HbA1c and FPG values, decreased body weight and 
BP at both 18- and 52-wk periods.21 Canagliflozin 
treatment also demonstrated a better effect upon 
glycemic control compared to glimepiride after 52-
week treatment in T2DM patients with metformin 
monotherapy.22 Considering the beneficial effect of 
canagliflozin therapy with patients subjected to 
insulinization, it could also be of interest for the 
management of T1DM. The effects of canagliflozin 
treatment upon attenuation of blood glucose after 
meal tolerance tests seem to also involve a non-renal 
mechanisms, possibly through inhibition of intestinal 
SGLT123,24 and augmented beta-cell function.25 
Since canagliflozin act on reducing RTG and 
increasing UGE, there is a parallel diuretic osmosis 
that favors the reduction of BP as can be observed by 
several phase III studies.12,20,21,26 This positive effect of 
canagliflozin treatment in the BP parameters is 
accompanied by increased incidence of osmotic 
diuresis-related adverse effects (e.g., pollakiuria 
[increased urine volume] and polyuria [increased urine 
frequency] and with low incidence of intravascular 
volume reduction-related adverse effects (e.g., 
orthostatic hypotension and postural dizziness).26 
Despite canagliflozin seeming to have a positive 
impact on BP control, caution is recommended in 
patients where low blood pressure may be a concern.27 
Some phase III studies conducted with T2DM 
patients with chronic kidney disease (CKD) at stage 
3a, where the estimated glomerular filtration rate 
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(eGFR) was >45 and <60 ml/min/1.73 m2, and at 
stage 3b, where the eGFR was >30 and <45 
ml/min/1.73 m2, canagliflozin treatment provided 
clinically important improvements in glycemic control 
and sustained reductions in body weight and BP over 
52 weeks, and was generally well tolerated in patients 
with T2DM and only within a subset of stage 3 
CKD.28,29 
 
Concluding remarks  
Based on considerable low rates of glycemic 
control in diabetic population and the exclusive 
mechanism of action and acceptable efficacy of 
SGLT2 inhibitors, this drug has a potential add-on 
therapy in T2DM patients whose blood glucose levels 
are inadequately controlled with other antidiabetic 
agents. Not only diabetic, but also subgroups with 
HbA1c levels in the range of 7-8%, overweight/obese 
patients or those with uncontrolled hypertension could 
benefit from canagliflozin therapy.30 Canagliflozin 
treatment should not be recommended in expansion 
need CKD patients as well as in elderly people and 
must be accompanied with caution in patients with 
established cardiovascular disease and high LDL-C 
levels until new clinical trials become available. A 
recent published review is recommended for a 
panoramic view of positive and negative impact of 
canagliflozin treatment.30  
Results from ongoing studies that include 
large randomized trials as well as experimental studies 
will help in understanding the long-term effects, safety 
and efficacy of canagliflozin and other SGLT2 
inhibitors (under evaluation) with respect to 
cardiometabolic aspects. 
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